Dr. Kristi McIntyre, MD
What this data tells you about Dr. McIntyre
Dr. Kristi McIntyre is a medical oncology in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. McIntyre performed 75,158 Medicare services across 3,457 unique beneficiaries.
Between the years covered by Open Payments, Dr. McIntyre received a total of $3,188 from 23 pharmaceutical and/or device companies across 44 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. McIntyre is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 16,600 | $43 | $136 |
| Anti-nausea injection (fosaprepitant) | 13,050 | $0 | $5 |
| Oxaliplatin chemotherapy injection | 10,000 | $0 | $33 |
| Iron sucrose injection (Venofer) | 9,000 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 8,445 | $2 | $20 |
| Paclitaxel chemotherapy injection | 3,948 | $0 | $8 |
| Immune globulin infusion (Octagam) | 2,050 | $34 | $235 |
| Dexamethasone injection (steroid) | 1,357 | $0 | $1 |
| Blood draw (venipuncture) | 1,136 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,048 | $8 | $36 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,040 | $1 | $114 |
| Comprehensive metabolic blood panel | 996 | $10 | $64 |
| Injection, granisetron hydrochloride, 100 mcg | 790 | $0 | $24 |
| Denosumab injection (Prolia/Xgeva) | 720 | $19 | $67 |
| Office visit, established patient (30-39 min) | 656 | $92 | $368 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 536 | $20 | $128 |
| Injection, fluorouracil, 500 mg | 420 | $2 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 316 | $23 | $157 |
| Administration of chemotherapy into vein, 1 hour or less | 304 | $104 | $707 |
| Injection, zoledronic acid, 1 mg | 249 | $6 | $431 |
| Injection, carboplatin, 50 mg | 189 | $2 | $300 |
| Immunoglobulin level test | 177 | $9 | $56 |
| Office visit, established patient, complex (40-54 min) | 133 | $135 | $496 |
| Drug injection, under skin or into muscle | 129 | $11 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 123 | $48 | $313 |
| Injection of additional new drug or substance into vein | 113 | $12 | $108 |
| Lactate dehydrogenase (enzyme) level | 104 | $6 | $31 |
| Infusion, normal saline solution , 1000 cc | 103 | $2 | $19 |
| Measurement of immunoglobulin light chains | 98 | $17 | $60 |
| Ferritin level test (iron stores) | 96 | $13 | $60 |
| Iron level test | 96 | $6 | $27 |
| Iron binding capacity test | 94 | $9 | $35 |
| Microscopic examination for white blood cells with manual cell count | 94 | $4 | $22 |
| Complete blood count (CBC), automated | 94 | $6 | $34 |
| Administration of chemotherapy into vein, each additional hour | 86 | $23 | $161 |
| Administration of additional new drug or substance into vein, 1 hour or less | 80 | $51 | $344 |
| Office visit, established patient (20-29 min) | 80 | $63 | $250 |
| Injection, diphenhydramine hcl, up to 50 mg | 77 | $1 | $7 |
| Unclassified drugs | 56 | $1 | $8 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 49 | $69 | $70 |
| Infusion into a vein for hydration, 31-60 minutes | 46 | $26 | $256 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 45 | $16 | $100 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 43 | $135 | $500 |
| Hospital follow-up visit, moderate complexity | 40 | $62 | $247 |
| Carcinoembryonic antigen (cea) protein level | 33 | $19 | $99 |
| New patient office visit, complex (60-74 min) | 32 | $149 | $709 |
| Echocardiogram, transthoracic | 30 | $136 | $828 |
| Hospital follow-up visit, high complexity | 30 | $93 | $357 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 29 | $1 | $19 |
| Infusion into a vein for hydration, each additional hour | 25 | $10 | $75 |
| Drawing of blood for a medical problem | 16 | $78 | $264 |
| Heart muscle strain imaging | 15 | $30 | $135 |
| New patient office visit (45-59 min) | 15 | $132 | $565 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 125 | 14 | $20 | $128 |
| Injection of drug or substance into vein | 13 | $30 | $247 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (65%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. McIntyre is a mixed practice specialist, with above-average Medicare volume (top 12% in TX), and consulting-driven industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. McIntyre experienced with pembrolizumab injection (keytruda)?
Does Dr. McIntyre receive payments from pharmaceutical companies?
How do Dr. McIntyre's costs compare to other medical oncologys in Dallas?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology